In this book we provide insights into liver - cancer and immunology. Experts in the field
provide an overview over fundamental immunological questions in liver cancer and
tumorimmunology which form the base for immune based approaches in HCC which gain increasing
interest in the community due to first promising results obtained in early clinical
trials.Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in
the United States. Treatment options are limited. Viral hepatitis is one of the major risk
factors for HCC which represents a typical inflammation-induced cancer.Immune-based treatment
approaches have revolutionized oncology in recent years. Various treatment strategies have
received FDA approval including dendritic cell vaccination for prostate cancer as well as
immune checkpoint inhibition targeting the CTLA4 or the PD1 PDL1 axis in melanoma lung and
kidney cancer. Additionally cell based therapies (adoptive T cell therapy CAR T cells and TCR
transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies
and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement
across the entire field of oncology providing a significant benefit to a minority of patients.
